{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T20:01:18Z","timestamp":1783195278390,"version":"3.54.6"},"reference-count":25,"publisher":"BMJ","issue":"12","funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Med Genet"],"accepted":{"date-parts":[[2018,8,29]]},"published-print":{"date-parts":[[2018,12]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>\n                     <jats:italic>BRCA1<\/jats:italic> and <jats:italic>BRCA2<\/jats:italic> (<jats:italic>BRCA1\/2<\/jats:italic>) variants classified ambiguously as variants of uncertain significance (VUS) are a major challenge for clinical genetic testing in breast cancer; their relevance to the cancer risk is unclear and the association with the response to specific <jats:italic>BRCA1\/2<\/jats:italic>-targeted agents is uncertain. To minimise the proportion of VUS in <jats:italic>BRCA1\/2<\/jats:italic>, we performed the multifactorial likelihood analysis and validated this method using an independent cohort of patients with breast cancer.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We used a data set of 2115 patients with breast cancer from the nationwide multicentre prospective Korean Hereditary Breast Cancer study. In total, 83 <jats:italic>BRCA1\/2<\/jats:italic> VUSs (<jats:italic>BRCA1<\/jats:italic>, n=26; <jats:italic>BRCA2<\/jats:italic>, n=57) were analysed. The multifactorial probability was estimated by combining the prior probability with the overall likelihood ratio derived from co-occurrence of each VUS with pathogenic variants, personal and family history, and tumour characteristics. The classification was compared with the interpretation according to the American College of Medical Genetics and Genomics\u2013Association for Molecular Pathology (ACMG\/AMP) guidelines. An external validation was conducted using independent data set of 810 patients.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>We were able to redefine 38 VUSs (<jats:italic>BRCA1<\/jats:italic>, n=10; <jats:italic>BRCA2<\/jats:italic>, n=28). The revised classification was highly correlated with the ACMG\/AMP guideline-based interpretation (<jats:italic>BRCA1<\/jats:italic>, p for trend=0.015; <jats:italic>BRCA2<\/jats:italic>, p=0.001). Our approach reduced the proportion of VUS from 19% (154\/810) to 8.9% (72\/810) in the retrospective validation data set.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>The classification in this study would minimise the \u2018uncertainty\u2019 in clinical interpretation, and this validated multifactorial model can be used for the reliable annotation of <jats:italic>BRCA1\/2<\/jats:italic> VUSs.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/jmedgenet-2018-105565","type":"journal-article","created":{"date-parts":[[2018,11,10]],"date-time":"2018-11-10T12:24:32Z","timestamp":1541852672000},"page":"794-802","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":29,"title":["Reclassification of <i>BRCA1<\/i> and <i>BRCA2<\/i> variants of uncertain significance: a multifactorial analysis of multicentre prospective cohort"],"prefix":"10.1136","volume":"55","clinical-trial-number":[{"clinical-trial-number":"nct02000622","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Jee-Soo","family":"Lee","sequence":"first","affiliation":[{"name":"Department of Laboratory Medicine, Hallym University Sacred Heart Hospital, Anyang, Republic of Korea"},{"name":"Department of Laboratory Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sohee","family":"Oh","sequence":"additional","affiliation":[{"name":"Department of Biostatistics SMG-SNU Boramae Medical Center, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sue Kyung","family":"Park","sequence":"additional","affiliation":[{"name":"Department of Preventive Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min-Hyuk","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Surgery, College of Medicine, Soonchunhyang University, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jong Won","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seongnam, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung-Won","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Surgery, Seoul National University Bundang Hospital, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byung Ho","family":"Son","sequence":"additional","affiliation":[{"name":"Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seongnam, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong-Young","family":"Noh","sequence":"additional","affiliation":[{"name":"Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeong Eon","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Surgery, Samsung Medical Center, Sungkyunkwan University, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai-Lin","family":"Park","sequence":"additional","affiliation":[{"name":"Department of Surgery, Kangnam CHA Hospital, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Man Jin","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung Im","family":"Cho","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young Kyung","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Hallym University Sacred Heart Hospital, Anyang, Republic of Korea"},{"name":"Department of Laboratory Medicine, Hallym University College of Medicine, Anyang, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung Sup","family":"Park","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moon-Woo","family":"Seong","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea"},{"name":"Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2018,11,10]]},"reference":[{"key":"2025100510484959000_55.12.794.1","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1056\/NEJMoa1706450","article-title":"Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation","volume":"377","author":"Robson","year":"2017","journal-title":"N Engl J Med"},{"key":"2025100510484959000_55.12.794.2","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-015-1934-1","article-title":"Understanding of BRCA VUS genetic results by breast cancer specialists","volume":"15","author":"Eccles","year":"2015","journal-title":"BMC Cancer"},{"key":"2025100510484959000_55.12.794.3","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.1245\/s10434-017-5959-3","article-title":"Clinical Decision-Making in Patients with Variant of Uncertain Significance in BRCA1 or BRCA2 Genes","volume":"24","author":"Welsh","year":"2017","journal-title":"Ann Surg Oncol"},{"key":"2025100510484959000_55.12.794.4","doi-asserted-by":"publisher","DOI":"10.1002\/humu.21627"},{"key":"2025100510484959000_55.12.794.5","doi-asserted-by":"publisher","DOI":"10.1086\/424388"},{"key":"2025100510484959000_55.12.794.6","doi-asserted-by":"publisher","DOI":"10.1002\/humu.20897"},{"key":"2025100510484959000_55.12.794.7","doi-asserted-by":"publisher","DOI":"10.1002\/humu.20880"},{"key":"2025100510484959000_55.12.794.8","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1038\/gim.2016.39","article-title":"Comparative analysis of BRCA1 and BRCA2 variants of uncertain significance in patients with breast cancer: a multifactorial probability-based model versus ACMG standards and guidelines for interpreting sequence variants","volume":"18","author":"Park","year":"2016","journal-title":"Genet Med"},{"key":"2025100510484959000_55.12.794.9","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0086836","article-title":"Multifactorial likelihood assessment of BRCA1 and BRCA2 missense variants confirms that BRCA1:c.122A>G(p.His41Arg) is a pathogenic mutation","volume":"9","author":"Whiley","year":"2014","journal-title":"PLoS One"},{"key":"2025100510484959000_55.12.794.10","doi-asserted-by":"publisher","DOI":"10.1086\/521032"},{"key":"2025100510484959000_55.12.794.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.clon.2010.11.007"},{"key":"2025100510484959000_55.12.794.12","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-012-2159-5"},{"key":"2025100510484959000_55.12.794.13","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdr304"},{"key":"2025100510484959000_55.12.794.14","doi-asserted-by":"publisher","DOI":"10.1038\/gim.2015.30"},{"key":"2025100510484959000_55.12.794.15","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.4143\/crt.2016.433","article-title":"Identification of a Novel BRCA1 Pathogenic Mutation in Korean Patients Following Reclassification of BRCA1 and BRCA2 Variants According to the ACMG Standards and Guidelines Using Relevant Ethnic Controls","volume":"49","author":"Park","year":"2017","journal-title":"Cancer Res Treat"},{"key":"2025100510484959000_55.12.794.16","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.breast.2017.03.006","article-title":"Suggestion of BRCA1 c.5339T>C (p.L1780P) variant confer from \u2019unknown significance' to \u2019Likely pathogenic' based on clinical evidence in Korea","volume":"33","author":"Ryu","year":"2017","journal-title":"Breast"},{"key":"2025100510484959000_55.12.794.17","doi-asserted-by":"crossref","first-page":"627","DOI":"10.4143\/crt.2016.292","article-title":"Clinically Significant Unclassified Variants in BRCA1 and BRCA2 genes among Korean Breast Cancer Patients","volume":"49","author":"Yoon","year":"2017","journal-title":"Cancer Res Treat"},{"key":"2025100510484959000_55.12.794.18","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-10-1214"},{"key":"2025100510484959000_55.12.794.19","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M310182200"},{"key":"2025100510484959000_55.12.794.20","doi-asserted-by":"publisher","DOI":"10.1097\/GIM.0b013e31816b5cae"},{"key":"2025100510484959000_55.12.794.21","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-010-1016-7"},{"key":"2025100510484959000_55.12.794.22","doi-asserted-by":"publisher","DOI":"10.1097\/GIM.0b013e318226fc15"},{"key":"2025100510484959000_55.12.794.23","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-16-2568"},{"key":"2025100510484959000_55.12.794.24","doi-asserted-by":"crossref","unstructured":"Lehmann BD , Pietenpol JA , Tan AR . Triple-negative breast cancer: molecular subtypes and new targets for therapy. Am Soc Clin Oncol Educ Book 2015:e31\u2013e39.doi:10.14694\/EdBook_AM.2015.35.e31","DOI":"10.14694\/EdBook_AM.2015.35.e31"},{"key":"2025100510484959000_55.12.794.25","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-009-0653-1"}],"container-title":["Journal of Medical Genetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jmedgenet-2018-105565","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T17:48:59Z","timestamp":1759686539000},"score":1,"resource":{"primary":{"URL":"https:\/\/jmg.bmj.com\/lookup\/doi\/10.1136\/jmedgenet-2018-105565"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,10]]},"references-count":25,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2018,11,22]]},"published-print":{"date-parts":[[2018,12]]}},"alternative-id":["10.1136\/jmedgenet-2018-105565"],"URL":"https:\/\/doi.org\/10.1136\/jmedgenet-2018-105565","relation":{},"ISSN":["0022-2593","1468-6244"],"issn-type":[{"value":"0022-2593","type":"print"},{"value":"1468-6244","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,10]]}}}